Financial impact of coverage for zoledronic acid and denosumab in cancer patients with bone metastases.

被引：1
|
作者：
Russell, M. W.
Bell, M. J.
Namjoshi, M.
Miller, J. D.
机构：
[1] RTI Hlth Solut, Waltham, MA USA
[2] RTI Hlth Solut, Manchester, Lancs, England
[3] Novartis Oncol US, E Hanover, NJ USA
来源：
JOURNAL OF CLINICAL ONCOLOGY | 2011年 / 29卷 / 15期
关键词：
D O I：
10.1200/jco.2011.29.15_suppl.e16515
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
e16515
引用
收藏
页数：1
相关论文
共 50 条
  • [1] Economic evaluation of denosumab compared with zoledronic acid in patients with hormone-refractory prostate cancer with bone metastases.
    Yu, A. P.
    Namjoshi, M.
    Xie, J.
    Parikh, K.
    Wu, E. Q.
    Guo, A.
    Culver, K. W.
    JOURNAL OF CLINICAL ONCOLOGY, 2011, 29 (15)
  • [2] Breast cancer bone metastases: denosumab or zoledronic acid?
    Gabri van der Pluijm
    Nature Reviews Endocrinology, 2011, 7 : 134 - 135
  • [3] CANCER Breast cancer bone metastases: denosumab or zoledronic acid?
    van der Pluijm, Gabri
    NATURE REVIEWS ENDOCRINOLOGY, 2011, 7 (03) : 134 - 135
  • [4] Denosumab and zoledronic acid treatment in patients with genitourinary cancers and bone metastases
    Costa, Luis
    Fizazi, Karim
    Saad, Fred
    Brown, Janet Elizabeth
    Von Moos, Roger
    Oudard, Stephane
    Sternberg, Cora N.
    Ganju, Vinod
    Miller, Kurt
    Wang, Huei
    Maniar, Tapan
    Braun, Ada
    JOURNAL OF CLINICAL ONCOLOGY, 2013, 31 (15)
  • [5] Population pharmacokinetic model for zoledronic acid (zometa) in patients with bone metastases.
    Booth, BP
    Rahman, A
    Ibrahim, A
    Scher, N
    Williams, G
    Schran, H
    Ma, P
    Hsu, C
    Gobburu, JV
    CLINICAL PHARMACOLOGY & THERAPEUTICS, 2003, 73 (02) : P67 - P67
  • [6] Cost-Effectiveness of Denosumab Compared With Zoledronic Acid in Patients With Breast Cancer and Bone Metastases
    Xie, Jipan
    Diener, Melissa
    Sorg, Rachael
    Wu, Eric Q.
    Namjoshi, Madhav
    CLINICAL BREAST CANCER, 2012, 12 (04) : 247 - 258
  • [7] Continuing benefit of zoledronic acid for the prevention of skeletal complications in breast cancer patients with bone metastases.
    Lipton, A.
    Chen, Y. M.
    Milton, S.
    BREAST CANCER RESEARCH AND TREATMENT, 2006, 100 : S62 - S62
  • [8] Compartmental pharmacokinetic (PK) analysis of zoledronic acid (ZA) in cancer patients (Pts) with bone metastases.
    Chen, TL
    Ravera, C
    Gerbeau, C
    Deckert, F
    Gauron, S
    Bardary, K
    Seaman, J
    CLINICAL PHARMACOLOGY & THERAPEUTICS, 2001, 69 (02) : P22 - P22
  • [9] The Zotect study: Effect of zoledronic acid (Zometa®) on Bone Metabolism in Patients with Nreast or Prostate cancer with Bone metastases.
    Gschwendt, J.
    Ziller, M.
    Kalder, M.
    Lux, C.
    Maurer, T.
    Muth, M.
    Schmidt, K.
    Hadji, P.
    ONKOLOGIE, 2010, 33 : 204 - 204
  • [10] IMPACT OF ZOLEDRONIC ACID ON FRACTURES AND MORTALITY IN PATIENTS WITH PROSTATE CANCER AND BONE METASTASES
    Henk, H. J.
    Kaura, S.
    EUROPEAN UROLOGY SUPPLEMENTS, 2010, 9 (02) : 284 - 285
12345